Novo Nordisk A/S is unique because its controlling voting stake is held by the Novo Nordisk Foundation, a Danish commercial foundation that operates the enterprise through a holding company structure to ensure long-term stability and research funding. Additionally, the public share classes feature massive institutional equity ownership from global asset management giants. Major institutional shareholders holding large passive and active positions include The Vanguard Group, BlackRock, Europacific Growth Fund, Capital World Growth and Income Fund, and various international index funds managing broad portfolios.